Revelation Biosciences (REVB) Competitors $0.76 -0.01 (-1.44%) Closing price 07/3/2025 03:59 PM EasternExtended Trading$0.76 0.00 (0.00%) As of 07/3/2025 04:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock REVB vs. PRFX, ADTX, PBM, OGEN, GRI, QLGN, ONCO, JAGX, VRAX, and PTNShould you be buying Revelation Biosciences stock or one of its competitors? The main competitors of Revelation Biosciences include PainReform (PRFX), Aditxt (ADTX), Psyence Biomedical (PBM), Oragenics (OGEN), GRI Bio (GRI), Qualigen Therapeutics (QLGN), Onconetix (ONCO), Jaguar Animal Health (JAGX), Virax Biolabs Group (VRAX), and Palatin Technologies (PTN). These companies are all part of the "pharmaceutical products" industry. Revelation Biosciences vs. Its Competitors PainReform Aditxt Psyence Biomedical Oragenics GRI Bio Qualigen Therapeutics Onconetix Jaguar Animal Health Virax Biolabs Group Palatin Technologies PainReform (NASDAQ:PRFX) and Revelation Biosciences (NASDAQ:REVB) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership, analyst recommendations and media sentiment. Does the media prefer PRFX or REVB? In the previous week, Revelation Biosciences had 4 more articles in the media than PainReform. MarketBeat recorded 4 mentions for Revelation Biosciences and 0 mentions for PainReform. Revelation Biosciences' average media sentiment score of 0.19 beat PainReform's score of 0.00 indicating that Revelation Biosciences is being referred to more favorably in the news media. Company Overall Sentiment PainReform Neutral Revelation Biosciences Neutral Do insiders and institutionals hold more shares of PRFX or REVB? 37.3% of PainReform shares are owned by institutional investors. Comparatively, 12.8% of Revelation Biosciences shares are owned by institutional investors. 34.4% of PainReform shares are owned by insiders. Comparatively, 2.3% of Revelation Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is PRFX or REVB more profitable? PainReform's return on equity of 0.00% beat Revelation Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets PainReformN/A N/A N/A Revelation Biosciences N/A -299.46%-115.36% Do analysts prefer PRFX or REVB? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PainReform 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Revelation Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has stronger valuation & earnings, PRFX or REVB? PainReform is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPainReformN/AN/A-$14.59M-$147.33-0.01Revelation BiosciencesN/AN/A-$15.04M-$102.61-0.01 Which has more volatility and risk, PRFX or REVB? PainReform has a beta of 0.56, suggesting that its stock price is 44% less volatile than the S&P 500. Comparatively, Revelation Biosciences has a beta of -0.08, suggesting that its stock price is 108% less volatile than the S&P 500. SummaryPainReform beats Revelation Biosciences on 7 of the 11 factors compared between the two stocks. Get Revelation Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for REVB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding REVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart REVB vs. The Competition Export to ExcelMetricRevelation BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.50M$2.91B$5.56B$9.03BDividend YieldN/A2.44%5.22%3.99%P/E Ratio-0.0121.5627.6920.25Price / SalesN/A241.84389.53161.89Price / CashN/A42.7336.8958.10Price / Book0.087.518.035.67Net Income-$15.04M-$55.14M$3.18B$249.21M7 Day PerformanceN/A4.61%2.93%3.28%1 Month Performance-11.68%0.90%1.72%3.95%1 Year Performance-97.26%5.40%34.39%20.98% Revelation Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)REVBRevelation Biosciences0.4583 of 5 stars$0.76-1.4%N/A-97.3%$3.50MN/A-0.0110PRFXPainReform0.7329 of 5 stars$1.44+2.1%N/A-22.1%$2.84MN/A-0.014Positive NewsADTXAditxtN/A$1.28-3.8%N/A-100.0%$2.82M$130K0.0060News CoveragePBMPsyence BiomedicalN/A$5.33+8.6%N/A-96.9%$2.80MN/A0.00N/AGap UpOGENOragenics0.2144 of 5 stars$3.82-5.7%N/A-95.1%$2.73M$40K-0.545Gap DownGRIGRI Bio3.2929 of 5 stars$1.29+1.6%$22.00+1,605.4%-94.6%$2.72MN/A-0.111Positive NewsQLGNQualigen TherapeuticsN/A$3.41-3.9%N/A-76.7%$2.61M$4.98M0.0050ONCOOnconetix0.2925 of 5 stars$4.77-1.2%N/A-99.1%$2.57M$2.52M0.0012JAGXJaguar Animal Health1.8569 of 5 stars$2.52+0.8%$60.00+2,281.0%-97.1%$2.55M$11.69M0.0050VRAXVirax Biolabs Group2.854 of 5 stars$0.79+1.5%$3.00+278.9%-29.1%$2.52M$160K0.005Positive NewsPTNPalatin TechnologiesN/A$0.09-44.6%N/AN/A$2.45M$350K-0.0630Gap DownHigh Trading Volume Related Companies and Tools Related Companies PainReform Competitors Aditxt Competitors Psyence Biomedical Competitors Oragenics Competitors GRI Bio Competitors Qualigen Therapeutics Competitors Onconetix Competitors Jaguar Animal Health Competitors Virax Biolabs Group Competitors Palatin Technologies Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:REVB) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredTrump’s BIGGEST setup yet.After another undefeated quarter, “Market Wizard” Larry Benedict is sounding the alarm on a $194 trillion mark...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revelation Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Revelation Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
